ScholarIQanswers from OpenAlex & ORCID
Wen‐Zhao Zhong
ResearcherPublications, citations & collaboration network
Wen‐Zhao Zhong is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Wen‐Zhao Zhong have?
ScholarIQindexed works
Wen‐Zhao Zhong has 503 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Wen‐Zhao Zhong have?
ScholarIQcitation count
Wen‐Zhao Zhong has 12,748 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Wen‐Zhao Zhong?
ScholarIQh-index
Wen‐Zhao Zhong has an h-index of 58 in OpenAlex.
What is the i10-index of Wen‐Zhao Zhong?
ScholarIQi10-index
Wen‐Zhao Zhong has an i10-index of 167 in OpenAlex.
What is the ORCID of Wen‐Zhao Zhong?
ScholarIQorcid
The ORCID for Wen‐Zhao Zhong is on the source record.
What is the OpenAlex record for Wen‐Zhao Zhong?
ScholarIQopenalex
The OpenAlex for Wen‐Zhao Zhong is on the source record.
What are the most-cited papers on Wen‐Zhao Zhong?
ScholarIQmost cited works
Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang, Jian Su, Zhi Xie, Si‐Yang Maggie Liu, Hai‐Yan Tu, Hua‐Jun Chen, Yue‐Li Sun, Qing Zhou, Jin‐Ji Yang, Xue‐Ning Yang, Jiaxin Lin, Hong‐Hong Yan, Hao-Ran Zhai, Li‐Xu Yan, Ri-Qiang Liao, Si-Pei Wu, Yi‐Long Wu
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen‐Zhao Zhong, Qun Wang, Weimin Mao, Lin Xu, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Hong‐Hong Yan, Xue‐Ning Yang, Qing Zhou, Yi‐Long Wu, Yi‐Long Wu, Qun Wang, Weimin Mao, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Zhi Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Siyu Wang, Jian Hu, Wei Liu, Wěi Li, Jianhua Shi
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu, Jian Su, Chao Zhang, Zhi Xie, Qing Zhou, Hai‐Yan Tu, Chong‐Rui Xu, Li‐Xu Yan, Yufa Li, Wen‐Zhao Zhong, Yi‐Long Wu
Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, Fabrice Barlési, Makoto Nishio, Ki Hyeong Lee, Jong Seok Lee, Wen‐Zhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian J. Hochmair, Filippo de Marinis, M.R. Migliorino, Igor Bondarenko, Shun Lü, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andrés F. Cardona, Thorsten Ruf, Johannes Noé, Benjamin Solomon
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y.S. Li, Bo Jiang, Jin‐Ji Yang, X.C. Zhang, Zhou Zhang, J.Y. Ye, Wen‐Zhao Zhong, Hai‐Yan Tu, H.J. Chen, Z. Wang, Chong‐Rui Xu, B.C. Wang, Hao Du, Shaokun Chuai, Han Han‐Zhang, Jian Su, Qing Zhou, Xue‐Ning Yang, Wanting Guo, Hong‐Hong Yan, Y.H. Liu, Li‐Xu Yan, Biao Huang, Mei-Mei Zheng, Yi‐Long Wu